PHI with Gastritis due to Campylobacter pylori
How does this condition affect your private health insurance?
Gastritis caused by *Helicobacter pylori* (formerly *Campylobacter pylori*) is a chronic inflammation of the stomach lining. This bacterium colonizes the gastric mucosa, leading to a spectrum of conditions from asymptomatic gastritis to peptic ulcers, MALT lymphoma, and gastric cancer. Symptoms can include abdominal pain, bloating, nausea, and indigestion, though many individuals remain asymptomatic. The infection is typically acquired orally, often in childhood, and can persist for decades if untreated, gradually damaging the stomach. Diagnosis usually involves endoscopy with biopsy, breath tests, or stool antigen tests, followed by antibiotic eradication therapy.
PKV Risk Assessment
However, some specialized PHI providers may insure you with a surcharge of up to 5%.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Acute symptomatic phase, if present, lasts days to weeks. The underlying infection is chronic if untreated.
Duration of Illness (Lifetime)
Chronic and lifelong if untreated. Successfully eradicated infections are usually cured, but complications may require ongoing management.
Cost of Treatment (Initial)
Approximately $300 - $3000 USD, covering diagnosis (e.g., breath test, endoscopy with biopsy) and a 7-14 day course of eradication therapy (antibiotics and proton pump inhibitors).
Cost of Treatment (Lifetime)
Minimal if successfully treated once. Can escalate significantly to tens of thousands or more if multiple treatment attempts are needed, or if complications like peptic ulcers, gastric bleeding, or gastric cancer develop requiring hospitalization, surgery, or long-term care.
Mortality Rate
Low (nearly zero directly from gastritis). Death risk increases significantly if complications like severe gastrointestinal bleeding or advanced gastric cancer develop, which are indirectly caused by the chronic infection.
Risk of Secondary Damages
High (e.g., peptic ulcers in 10-20%, chronic atrophic gastritis, MALT lymphoma in <1%, gastric adenocarcinoma in 1-3% over decades if untreated).
Probability of Full Recovery
High (80-90% with appropriate first-line eradication therapy), meaning successful elimination of the bacterium and resolution of gastritis, though some mucosal changes may persist. Recurrence after successful eradication is low.
Underlying Disease Risk
High probability that the *H. pylori* infection itself is an underlying cause for other conditions. For instance, approximately 10-20% of infected individuals will develop peptic ulcer disease, and there is a 3-6 fold increased lifetime risk of gastric cancer.